Chronic Idiopathic Urticaria Pipeline, Clinical Trials, Emerging Drugs ... - Benzinga

JSPRW Stock  USD 0.20  0.01  5.26%   
Slightly above 55% of Jasper Therapeutics' sophisticated investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Jasper Therapeutics suggests that some traders are interested. Jasper Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Jasper Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Chronic Idiopathic Urticaria Pipeline, Clinical Trials, Emerging Drugs ... Benzinga

Read at news.google.com
Google News at Macroaxis
  

Jasper Therapeutics Fundamental Analysis

We analyze Jasper Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Jasper Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Peers

Trending Equities

BBY  2.08   
0%
100.0%
TGT  1.71   
0%
82.0%
INTC  1.69   
0%
81.0%
AA  1.20   
0%
57.0%
AAPL  1.02   
0%
49.0%
C  1.01   
0%
48.0%
HD  0.45   
0%
21.0%
IBM  0.22   
0%
10.0%
UPS  0.03   
0%
1.0%
MET  0.02   
1.0%
0%
CVX  0.11   
5.0%
0%
CVS  0.18   
8.0%
0%
S  0.46   
22.0%
0%
T  0.47   
22.0%
0%
AAL  0.82   
39.0%
0%
WFC  1.35   
64.0%
0%

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.